首页 > 最新文献

Expert Review of Clinical Immunology最新文献

英文 中文
Transcriptomic observations of intra and extracellular immunotherapy targets for pediatric brain tumors. 小儿脑肿瘤细胞内和细胞外免疫疗法靶点的转录组观察。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-08-18 DOI: 10.1080/1744666X.2024.2390023
Stephen C Frederico, Itay Raphael, Michal Nisnboym, Sakibul Huq, Brent T Schlegel, Chaim T Sneiderman, Sydney A Jackson, Anya Jain, Michael R Olin, Brian R Rood, Ian F Pollack, Eugene I Hwang, Dhivyaa Rajasundaram, Gary Kohanbash

Objectives: Despite surgical resection, chemoradiation, and targeted therapy, brain tumors remain a leading cause of cancer-related death in children. Immunotherapy has shown some promise and is actively being investigated for treating childhood brain tumors. However, a critical step in advancing immunotherapy for these patients is to uncover targets that can be effectively translated into therapeutic interventions.

Methods: In this study, our team performed a transcriptomic analysis across pediatric brain tumor types to identify potential targets for immunotherapy. Additionally, we assessed components that may impact patient response to immunotherapy, including the expression of genes essential for antigen processing and presentation, inhibitory ligands and receptors, interferon signature, and overall predicted T cell infiltration.

Results: We observed distinct expression patterns across tumor types. These included elevated expression of antigen genes and antigen processing machinery in some tumor types while other tumors had elevated inhibitory checkpoint receptors, known to be associated with response to checkpoint inhibitor immunotherapy.

Conclusion: These findings suggest that pediatric brain tumors exhibit distinct potential for specific immunotherapies. We believe our findings can guide investigators in their assessment of appropriate immunotherapy classes and targets in pediatric brain tumors.

目标:尽管采取了手术切除、化学放疗和靶向治疗等方法,脑肿瘤仍然是导致儿童癌症相关死亡的主要原因。免疫疗法已显示出一定的前景,目前正在积极研究用于治疗儿童脑肿瘤。然而,为这些患者推进免疫疗法的一个关键步骤是发现可有效转化为治疗干预措施的靶点:在这项研究中,我们的团队对各种类型的儿童脑肿瘤进行了转录组分析,以确定免疫疗法的潜在靶点。此外,我们还评估了可能影响患者对免疫疗法反应的成分,包括抗原处理和递呈、抑制性配体和受体、干扰素特征以及总体预测的T细胞浸润所必需的基因的表达:结果:我们观察到不同肿瘤类型有不同的表达模式。结果:我们观察到不同肿瘤类型有不同的表达模式,包括一些肿瘤类型中抗原基因和抗原处理机制的表达升高,而另一些肿瘤中抑制性检查点受体的表达升高,已知这与检查点抑制剂免疫疗法的反应有关:这些发现表明,小儿脑肿瘤对特异性免疫疗法具有独特的潜力。我们相信,我们的研究结果可以指导研究人员评估小儿脑肿瘤的适当免疫疗法类别和靶点。
{"title":"Transcriptomic observations of intra and extracellular immunotherapy targets for pediatric brain tumors.","authors":"Stephen C Frederico, Itay Raphael, Michal Nisnboym, Sakibul Huq, Brent T Schlegel, Chaim T Sneiderman, Sydney A Jackson, Anya Jain, Michael R Olin, Brian R Rood, Ian F Pollack, Eugene I Hwang, Dhivyaa Rajasundaram, Gary Kohanbash","doi":"10.1080/1744666X.2024.2390023","DOIUrl":"10.1080/1744666X.2024.2390023","url":null,"abstract":"<p><strong>Objectives: </strong>Despite surgical resection, chemoradiation, and targeted therapy, brain tumors remain a leading cause of cancer-related death in children. Immunotherapy has shown some promise and is actively being investigated for treating childhood brain tumors. However, a critical step in advancing immunotherapy for these patients is to uncover targets that can be effectively translated into therapeutic interventions.</p><p><strong>Methods: </strong>In this study, our team performed a transcriptomic analysis across pediatric brain tumor types to identify potential targets for immunotherapy. Additionally, we assessed components that may impact patient response to immunotherapy, including the expression of genes essential for antigen processing and presentation, inhibitory ligands and receptors, interferon signature, and overall predicted T cell infiltration.</p><p><strong>Results: </strong>We observed distinct expression patterns across tumor types. These included elevated expression of antigen genes and antigen processing machinery in some tumor types while other tumors had elevated inhibitory checkpoint receptors, known to be associated with response to checkpoint inhibitor immunotherapy.</p><p><strong>Conclusion: </strong>These findings suggest that pediatric brain tumors exhibit distinct potential for specific immunotherapies. We believe our findings can guide investigators in their assessment of appropriate immunotherapy classes and targets in pediatric brain tumors.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1411-1420"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anakinra as first-line monotherapy for new-onset steroid-naïve sJIA patients. Anakinra 作为新发类固醇无效 sJIA 患者的一线单药疗法。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-30 DOI: 10.1080/1744666X.2024.2384703
Maria Vincenza Mastrolia, Sarah Abu-Rumeileh, Ilaria Maccora, Valerio Maniscalco, Edoardo Marrani, Ilaria Pagnini, Andrea Taddio, Gabriele Simonini
{"title":"Anakinra as first-line monotherapy for new-onset steroid-naïve sJIA patients.","authors":"Maria Vincenza Mastrolia, Sarah Abu-Rumeileh, Ilaria Maccora, Valerio Maniscalco, Edoardo Marrani, Ilaria Pagnini, Andrea Taddio, Gabriele Simonini","doi":"10.1080/1744666X.2024.2384703","DOIUrl":"10.1080/1744666X.2024.2384703","url":null,"abstract":"","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1293-1295"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathogen-specific cell-mediated immunity to guide the management of cytomegalovirus in solid organ transplantation: state of the art clinical review. 病原体特异性细胞介导免疫指导实体器官移植中巨细胞病毒的管理:最新临床回顾。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-24 DOI: 10.1080/1744666X.2024.2384060
Raymund R Razonable

Introduction: Cytomegalovirus (CMV) is a common opportunistic infection after solid organ transplantation, with significant impact on morbidity and long-term survival. Despite advances in diagnostics and therapeutics, the management of CMV remains very challenging.

Areas covered: This article reviews emerging data on the clinical utility of laboratory assays that quantify cell-mediated immune responses to CMV. Observational studies have consistently demonstrated that a deficiency in pathogen-specific cell-mediated immunity is correlated with a heightened risk of primary, reactivation or recurrent CMV after transplantation. A limited number of interventional studies have recently investigated cell-mediated immune assays in guiding the prevention and treatment of CMV infection after solid organ transplantation.

Expert opinion: The pathogenesis and outcome of CMV after solid organ transplantion reflect the interplay between viral replication and CMV-specific immune reconstitution. Research in CMV-specific cell-mediated immunity paved way for the development of several laboratory assays that may assist clinicians in predicting the risk of CMV after transplantation, individualize the approach to CMV disease prevention, guide the need and duration of treatment of CMV infection, and predict the risk of relapse after treatment. More interventional studies are needed to further solidify the role of cell-mediated immune assays in various clinical situations after transplantation.

简介:巨细胞病毒(CMV)是实体器官移植后常见的机会性感染:巨细胞病毒(CMV)是实体器官移植后常见的机会性感染,对发病率和长期生存有重大影响。尽管在诊断和治疗方面取得了进步,但巨细胞病毒的管理仍然极具挑战性:这篇文章回顾了量化 CMV 细胞介导免疫反应的实验室检测方法的临床实用性的新数据。观察性研究一致表明,病原体特异性细胞介导免疫的缺乏与移植后原发性、再激活或复发性 CMV 风险的增加相关。最近,少数干预性研究对细胞介导免疫测定进行了调查,以指导预防和治疗实体器官移植后的 CMV 感染:专家观点:CMV 在实体器官移植后的发病机制和结局反映了病毒复制与 CMV 特异性免疫重建之间的相互作用。对CMV特异性细胞介导免疫的研究为多种实验室检测方法的开发铺平了道路,这些检测方法可帮助临床医生预测移植后CMV感染的风险、个性化的CMV疾病预防方法、指导CMV感染治疗的必要性和持续时间,以及预测治疗后复发的风险。要进一步巩固细胞介导免疫测定在移植后各种临床情况中的作用,还需要更多的介入性研究。
{"title":"Pathogen-specific cell-mediated immunity to guide the management of cytomegalovirus in solid organ transplantation: state of the art clinical review.","authors":"Raymund R Razonable","doi":"10.1080/1744666X.2024.2384060","DOIUrl":"10.1080/1744666X.2024.2384060","url":null,"abstract":"<p><strong>Introduction: </strong>Cytomegalovirus (CMV) is a common opportunistic infection after solid organ transplantation, with significant impact on morbidity and long-term survival. Despite advances in diagnostics and therapeutics, the management of CMV remains very challenging.</p><p><strong>Areas covered: </strong>This article reviews emerging data on the clinical utility of laboratory assays that quantify cell-mediated immune responses to CMV. Observational studies have consistently demonstrated that a deficiency in pathogen-specific cell-mediated immunity is correlated with a heightened risk of primary, reactivation or recurrent CMV after transplantation. A limited number of interventional studies have recently investigated cell-mediated immune assays in guiding the prevention and treatment of CMV infection after solid organ transplantation.</p><p><strong>Expert opinion: </strong>The pathogenesis and outcome of CMV after solid organ transplantion reflect the interplay between viral replication and CMV-specific immune reconstitution. Research in CMV-specific cell-mediated immunity paved way for the development of several laboratory assays that may assist clinicians in predicting the risk of CMV after transplantation, individualize the approach to CMV disease prevention, guide the need and duration of treatment of CMV infection, and predict the risk of relapse after treatment. More interventional studies are needed to further solidify the role of cell-mediated immune assays in various clinical situations after transplantation.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1367-1380"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies. 脊柱关节炎和银屑病关节炎的治疗争议:聚焦生物制剂和靶向疗法。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-29 DOI: 10.1080/1744666X.2024.2384705
Fadi Kharouf, Dafna D Gladman

Introduction: There are several treatment controversies that have emerged in spondyloarthritis and psoriatic arthritis. These are related to the nature of the conditions as well as to the use of medications.

Areas covered: This review, which included a search of PubMed database as well as the references within the articles provides an overview of the nature of spondyloarthritis, controversy over the inclusion of psoriatic arthritis (PsA) as a peripheral spondyloarthritis, and a summary of current treatments for both PsA and axial spondyloarthritis (axSpA), with special emphasis on targeted therapy. The review highlights the differences in response to certain medications, particularly biologic therapy and summarizes the randomized controlled trials in psoriatic arthritis and axial spondyloarthritis providing data about the responses in table format.

Expert opinion: There is a need for better outcome measures in axSpA. Currently, the measures are subjective. Imaging may be more appropriate but there is a need for research into the reliability and responsiveness of imaging techniques. In PsA, there may also be better response measures and research into the reliability and responsiveness of available measures is underway. There is also a need for novel therapies as well as biomarkers for response in both diseases.

导言:脊柱关节炎和银屑病关节炎在治疗方面出现了一些争议。这些争议与疾病的性质以及药物的使用有关:这篇综述包括对 PubMed 数据库的检索以及文章中的参考文献,概述了脊柱关节炎的性质、将银屑病关节炎 (PsA) 作为外周脊柱关节炎的争议、PsA 和轴性脊柱关节炎 (axSpA) 目前的治疗方法,并特别强调了靶向治疗。综述强调了对某些药物(尤其是生物疗法)反应的差异,并总结了银屑病关节炎和轴性脊柱关节炎的随机对照试验,以表格形式提供了有关反应的数据:轴性脊柱关节炎需要更好的疗效衡量标准。目前,衡量标准都是主观的。成像可能更合适,但需要对成像技术的可靠性和响应性进行研究。对于 PsA,也可能有更好的反应测量方法,目前正在对现有测量方法的可靠性和反应性进行研究。此外,这两种疾病都需要新型疗法和反应生物标志物。
{"title":"Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies.","authors":"Fadi Kharouf, Dafna D Gladman","doi":"10.1080/1744666X.2024.2384705","DOIUrl":"10.1080/1744666X.2024.2384705","url":null,"abstract":"<p><strong>Introduction: </strong>There are several treatment controversies that have emerged in spondyloarthritis and psoriatic arthritis. These are related to the nature of the conditions as well as to the use of medications.</p><p><strong>Areas covered: </strong>This review, which included a search of PubMed database as well as the references within the articles provides an overview of the nature of spondyloarthritis, controversy over the inclusion of psoriatic arthritis (PsA) as a peripheral spondyloarthritis, and a summary of current treatments for both PsA and axial spondyloarthritis (axSpA), with special emphasis on targeted therapy. The review highlights the differences in response to certain medications, particularly biologic therapy and summarizes the randomized controlled trials in psoriatic arthritis and axial spondyloarthritis providing data about the responses in table format.</p><p><strong>Expert opinion: </strong>There is a need for better outcome measures in axSpA. Currently, the measures are subjective. Imaging may be more appropriate but there is a need for research into the reliability and responsiveness of imaging techniques. In PsA, there may also be better response measures and research into the reliability and responsiveness of available measures is underway. There is also a need for novel therapies as well as biomarkers for response in both diseases.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1381-1400"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epstein-Barr virus-driven lymphoproliferation in inborn errors of immunity: a diagnostic and therapeutic challenge. 先天性免疫错误中由 Epstein-Barr 病毒驱动的淋巴细胞增殖:诊断和治疗的挑战。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-30 DOI: 10.1080/1744666X.2024.2386427
Prabal Barman, Suprit Basu, Taru Goyal, Saniya Sharma, Sangeetha Siniah, Rahul Tyagi, Kaushal Sharma, Ankur K Jindal, Rakesh K Pilania, Pandiarajan Vignesh, Manpreet Dhaliwal, Deepti Suri, Amit Rawat, Surjit Singh

Introduction: Inborn errors of immunity (IEI) are a group of genetically heterogeneous disorders with a wide-ranging clinical phenotype, varying from increased predisposition to infections to dysregulation of the immune system, including autoimmune phenomena, autoinflammatory disorders, lymphoproliferation, and malignancy. Lymphoproliferative disorder (LPD) in IEI refers to the nodal or extra-nodal and persistent or recurrent clonal or non-clonal proliferation of lymphoid cells in the clinical context of an inherited immunodeficiency or immune dysregulation. The Epstein-Barr virus (EBV) plays a significant role in the etiopathogenesis of LPD in IEIs. In patients with specific IEIs, lack of immune surveillance can lead to an uninhibited proliferation of EBV-infected cells that may result in chronic active EBV infection, hemophagocytic lymphohistiocytosis, and LPD, particularly lymphomas.

Areas covered: We intend to discuss the pathogenesis, diagnosis, and treatment modalities directed toward EBV-associated LPD in patients with distinct IEIs.

Expert opinion: EBV-driven lymphoproliferation in IEIs presents a diagnostic and therapeutic problem that necessitates a comprehensive understanding of host-pathogen interactions, immune dysregulation, and personalized treatment approaches. A multidisciplinary approach involving immunologists, hematologists, infectious disease specialists, and geneticists is paramount to addressing the diagnostic and therapeutic challenges posed by this intriguing yet formidable clinical entity.

导言:先天性免疫错误(IEI)是一组遗传异质性疾病,其临床表型多种多样,从感染易感性增加到免疫系统失调,包括自身免疫现象、自身炎症性疾病、淋巴细胞增生和恶性肿瘤。IEI 中的淋巴细胞增生性疾病(LPD)是指在遗传性免疫缺陷或免疫失调的临床背景下,淋巴细胞结节性或结节外、持续性或复发性克隆性或非克隆性增生。Epstein-Barr 病毒(EBV)在 IEIs 的 LPD 发病机制中起着重要作用。在特定的 IEIs 患者中,免疫监视的缺乏会导致 EBV 感染细胞不受抑制地增殖,从而可能导致慢性活动性 EBV 感染、嗜血细胞性淋巴组织细胞增多症和 LPD,尤其是淋巴瘤:我们将讨论不同 IEI 患者中 EBV 相关 LPD 的发病机制、诊断和治疗方法:EBV驱动的IEIs淋巴细胞增生是一个诊断和治疗问题,需要全面了解宿主与病原体的相互作用、免疫失调和个性化治疗方法。免疫学家、血液学家、传染病专家和遗传学家共同参与的多学科方法对于解决这一有趣而又可怕的临床实体所带来的诊断和治疗难题至关重要。
{"title":"Epstein-Barr virus-driven lymphoproliferation in inborn errors of immunity: a diagnostic and therapeutic challenge.","authors":"Prabal Barman, Suprit Basu, Taru Goyal, Saniya Sharma, Sangeetha Siniah, Rahul Tyagi, Kaushal Sharma, Ankur K Jindal, Rakesh K Pilania, Pandiarajan Vignesh, Manpreet Dhaliwal, Deepti Suri, Amit Rawat, Surjit Singh","doi":"10.1080/1744666X.2024.2386427","DOIUrl":"10.1080/1744666X.2024.2386427","url":null,"abstract":"<p><strong>Introduction: </strong>Inborn errors of immunity (IEI) are a group of genetically heterogeneous disorders with a wide-ranging clinical phenotype, varying from increased predisposition to infections to dysregulation of the immune system, including autoimmune phenomena, autoinflammatory disorders, lymphoproliferation, and malignancy. Lymphoproliferative disorder (LPD) in IEI refers to the nodal or extra-nodal and persistent or recurrent clonal or non-clonal proliferation of lymphoid cells in the clinical context of an inherited immunodeficiency or immune dysregulation. The Epstein-Barr virus (EBV) plays a significant role in the etiopathogenesis of LPD in IEIs. In patients with specific IEIs, lack of immune surveillance can lead to an uninhibited proliferation of EBV-infected cells that may result in chronic active EBV infection, hemophagocytic lymphohistiocytosis, and LPD, particularly lymphomas.</p><p><strong>Areas covered: </strong>We intend to discuss the pathogenesis, diagnosis, and treatment modalities directed toward EBV-associated LPD in patients with distinct IEIs.</p><p><strong>Expert opinion: </strong>EBV-driven lymphoproliferation in IEIs presents a diagnostic and therapeutic problem that necessitates a comprehensive understanding of host-pathogen interactions, immune dysregulation, and personalized treatment approaches. A multidisciplinary approach involving immunologists, hematologists, infectious disease specialists, and geneticists is paramount to addressing the diagnostic and therapeutic challenges posed by this intriguing yet formidable clinical entity.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1331-1346"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aleukemic variant of T-cell large granular lymphocyte leukemia in patients with rheumatoid arthritis - diagnostically challenging subtype. 类风湿性关节炎患者中的 T 细胞大颗粒淋巴细胞白血病 Aleukemic 变异型--诊断上具有挑战性的亚型。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-24 DOI: 10.1080/1744666X.2024.2384057
Vadim Gorodetskiy, Andrey Sudarikov

Introduction: The typical clinical manifestations of T-cell large granular lymphocyte (T-LGL) leukemia are an increase in the number of large granular lymphocytes (LGLs) in the blood > 2000 cells/μL, neutropenia, and splenomegaly. In rare cases of so-called 'aleukemic' T-LGL leukemia, the number of LGLs is <400-500 cells/μL. In patients with rheumatoid arthritis (RA), distinguishing T-LGL leukemia with low tumor burden in the blood and bone marrow from Felty syndrome (FS) poses diagnostic challenges.

Areas covered: This review aimed to describe the basic characteristics and variants of aleukemic T-LGL leukemia, with a special focus on aleukemic T-LGL leukemia with massive splenomegaly (splenic variant of T-LGL leukemia) and differential diagnosis of such cases with hepatosplenic T-cell lymphoma. The significance of mutations in the signal transducer and activator of transcription 3 (STAT3) gene for distinguishing aleukemic RA-associated T-LGL leukemia from FS is discussed, along with the evolution of the T-LGL leukemia diagnostic criteria. PubMed database was used to search for the most relevant literature.

Expert opinion: Evaluation of STAT3 mutations in the blood and bone marrow using next-generation sequencing, as well as a comprehensive spleen study, may be necessary to establish a diagnosis of aleukemic RA-associated T-LGL leukemia.

导读:T细胞大颗粒淋巴细胞(T-LGL)白血病的典型临床表现是血液中大颗粒淋巴细胞(LGL)数量增加T细胞大颗粒淋巴细胞(T-LGL)白血病的典型临床表现是血液中大颗粒淋巴细胞(LGL)数量增加,大于2000个/μL,中性粒细胞减少,脾脏肿大。在极少数所谓的 "白血病 "T-LGL白血病病例中,大颗粒淋巴细胞的数量被覆盖:本综述旨在描述白血病型T-LGL白血病的基本特征和变异型,特别关注伴有脾脏大量肿大的白血病型T-LGL白血病(T-LGL白血病脾脏变异型),以及此类病例与肝脾T细胞淋巴瘤的鉴别诊断。本文讨论了信号转导和转录激活因子3(STAT3)基因突变对区分白血病RA相关T-LGL白血病和FS的意义,以及T-LGL白血病诊断标准的演变。PubMed数据库用于搜索最相关的文献:专家观点:要确诊白血病RA相关T-LGL白血病,可能需要使用新一代测序技术评估血液和骨髓中的STAT3突变,并进行全面的脾脏研究。
{"title":"Aleukemic variant of T-cell large granular lymphocyte leukemia in patients with rheumatoid arthritis - diagnostically challenging subtype.","authors":"Vadim Gorodetskiy, Andrey Sudarikov","doi":"10.1080/1744666X.2024.2384057","DOIUrl":"10.1080/1744666X.2024.2384057","url":null,"abstract":"<p><strong>Introduction: </strong>The typical clinical manifestations of T-cell large granular lymphocyte (T-LGL) leukemia are an increase in the number of large granular lymphocytes (LGLs) in the blood > 2000 cells/μL, neutropenia, and splenomegaly. In rare cases of so-called 'aleukemic' T-LGL leukemia, the number of LGLs is <400-500 cells/μL. In patients with rheumatoid arthritis (RA), distinguishing T-LGL leukemia with low tumor burden in the blood and bone marrow from Felty syndrome (FS) poses diagnostic challenges.</p><p><strong>Areas covered: </strong>This review aimed to describe the basic characteristics and variants of aleukemic T-LGL leukemia, with a special focus on aleukemic T-LGL leukemia with massive splenomegaly (splenic variant of T-LGL leukemia) and differential diagnosis of such cases with hepatosplenic T-cell lymphoma. The significance of mutations in the signal transducer and activator of transcription 3 (<i>STAT3</i>) gene for distinguishing aleukemic RA-associated T-LGL leukemia from FS is discussed, along with the evolution of the T-LGL leukemia diagnostic criteria. PubMed database was used to search for the most relevant literature.</p><p><strong>Expert opinion: </strong>Evaluation of <i>STAT3</i> mutations in the blood and bone marrow using next-generation sequencing, as well as a comprehensive spleen study, may be necessary to establish a diagnosis of aleukemic RA-associated T-LGL leukemia.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1323-1330"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine learning and artificial intelligence within pediatric autoimmune diseases: applications, challenges, future perspective. 儿科自身免疫性疾病中的机器学习和人工智能:应用、挑战和未来展望。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-01 Epub Date: 2024-06-14 DOI: 10.1080/1744666X.2024.2359019
Parniyan Sadeghi, Hanie Karimi, Atiye Lavafian, Ronak Rashedi, Noosha Samieefar, Sajad Shafiekhani, Nima Rezaei

Introduction: Autoimmune disorders affect 4.5% to 9.4% of children, significantly reducing their quality of life. The diagnosis and prognosis of autoimmune diseases are uncertain because of the variety of onset and development. Machine learning can identify clinically relevant patterns from vast amounts of data. Hence, its introduction has been beneficial in the diagnosis and management of patients.

Areas covered: This narrative review was conducted through searching various electronic databases, including PubMed, Scopus, and Web of Science. This study thoroughly explores the current knowledge and identifies the remaining gaps in the applications of machine learning specifically in the context of pediatric autoimmune and related diseases.

Expert opinion: Machine learning algorithms have the potential to completely change how pediatric autoimmune disorders are identified, treated, and managed. Machine learning can assist physicians in making more precise and fast judgments, identifying new biomarkers and therapeutic targets, and personalizing treatment strategies for each patient by utilizing massive datasets and powerful analytics.

简介4.5%至9.4%的儿童患有自身免疫性疾病,大大降低了他们的生活质量。由于自身免疫性疾病的发病和发展各不相同,因此其诊断和预后并不确定。机器学习可以从海量数据中识别与临床相关的模式。因此,引入机器学习有利于患者的诊断和管理:本综述通过搜索各种电子数据库(包括PubMed、Scopus和Web of Science)进行。本研究深入探讨了机器学习在儿科自身免疫性疾病及相关疾病应用方面的现有知识,并找出了尚存的差距:机器学习算法有可能彻底改变儿科自身免疫性疾病的识别、治疗和管理方式。机器学习可以帮助医生做出更精确、更快速的判断,确定新的生物标记物和治疗目标,并通过利用海量数据集和强大的分析功能为每位患者制定个性化治疗策略。
{"title":"Machine learning and artificial intelligence within pediatric autoimmune diseases: applications, challenges, future perspective.","authors":"Parniyan Sadeghi, Hanie Karimi, Atiye Lavafian, Ronak Rashedi, Noosha Samieefar, Sajad Shafiekhani, Nima Rezaei","doi":"10.1080/1744666X.2024.2359019","DOIUrl":"10.1080/1744666X.2024.2359019","url":null,"abstract":"<p><strong>Introduction: </strong>Autoimmune disorders affect 4.5% to 9.4% of children, significantly reducing their quality of life. The diagnosis and prognosis of autoimmune diseases are uncertain because of the variety of onset and development. Machine learning can identify clinically relevant patterns from vast amounts of data. Hence, its introduction has been beneficial in the diagnosis and management of patients.</p><p><strong>Areas covered: </strong>This narrative review was conducted through searching various electronic databases, including PubMed, Scopus, and Web of Science. This study thoroughly explores the current knowledge and identifies the remaining gaps in the applications of machine learning specifically in the context of pediatric autoimmune and related diseases.</p><p><strong>Expert opinion: </strong>Machine learning algorithms have the potential to completely change how pediatric autoimmune disorders are identified, treated, and managed. Machine learning can assist physicians in making more precise and fast judgments, identifying new biomarkers and therapeutic targets, and personalizing treatment strategies for each patient by utilizing massive datasets and powerful analytics.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1219-1236"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141075825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sicca syndrome/Sjögren's disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management. 与癌症免疫疗法相关的筛查综合征/谢格伦氏病:临床表现、生物标志物和治疗方法综述。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-01 Epub Date: 2024-06-25 DOI: 10.1080/1744666X.2024.2370327
Sandra Gofinet Pasoto, André Silva Franco, Clovis Artur Silva, Eloisa Bonfa

Introduction: Almost one-quarter of immune checkpoint inhibitor (ICI) recipients experience sicca syndrome, while Sjögren's disease (SjD) is estimated at 0.3-2.5%, possibly underreported.

Areas covered: This narrative review (Medline/Embase until January/31/2024) addresses the pathophysiology, incidence, demographic/clinical features, biomarkers, labial salivary gland biopsy (LSGB), fulfillment of the idiopathic SjD (iSjD) classificatory criteria, differential diagnosis, and management of sicca syndrome/SjD associated with ICIs.

Expert opinion: SjD associated with ICIs is underdiagnosed, since studies that performed the mandatory SjD investigation identified that 40-60% of patients with sicca syndrome associated with ICIs meet the iSjD classificatory criteria. LSGB played a fundamental role in recognizing these cases, as most of them had negative anti-Ro/SS-A antibody. Despite the finding of focal lymphocytic sialoadenitis in LSGB samples mimicking iSjD, immunohistochemical analysis provided novel evidence of a distinct pattern for sicca syndrome/SjD associated with ICIs compared to iSjD. The former has scarcity of B lymphocytes, which are a hallmark of iSjD. Additionally, patients with sicca syndrome/SjD associated with ICIs have demographical/clinical/serological and treatment response dissimilarities compared to iSjD. Dryness symptoms are more acute in the former than in iSjD, with predominance of xerostomia over xerophthalmia, and partial/complete response to glucocorticoids. Dryness symptoms in ICI-treated patients warrant prompt SjD investigation.

简介:近四分之一的免疫检查点抑制剂(ICI)受者会出现疱疹综合征,而斯约格伦病(SjD)的发病率估计为0.3%-2.5%,可能报告不足:这篇叙述性综述(Medline/Embase,截止日期为2024年1月31日)探讨了与ICIs相关的虹膜睫状体综合征/SjD的病理生理学、发病率、人口统计学/临床特征、生物标志物、唇唾液腺活检(LSGB)、特发性SjD(iSjD)分类标准的执行情况、鉴别诊断和管理:专家意见:与 ICIs 相关的 SjD 诊断不足,因为进行强制性 SjD 调查的研究发现,40%-60% 与 ICIs 相关的筛查综合征患者符合 iSjD 分类标准。LSGB 在识别这些病例方面发挥了重要作用,因为他们中的大多数人抗 Ro/SS-A 抗体呈阴性。尽管在 LSGB 样本中发现了模仿 iSjD 的局灶性淋巴细胞性唾液腺炎,但免疫组化分析提供了新的证据,证明与 iSjD 相比,与 ICIs 相关的筛查综合征/SjD 有着不同的模式。前者缺少 B 淋巴细胞,而 B 淋巴细胞是 iSjD 的标志。此外,与 iSjD 相比,伴有 ICIs 的筛查综合征/SjD 患者在人口学/临床/血清学和治疗反应方面也存在差异。与 iSjD 相比,前者的干燥症状更严重,主要表现为口干症而非眼干症,对糖皮质激素有部分/完全反应。接受 ICI 治疗的患者出现干燥症状时,应立即进行 SjD 检查。
{"title":"Sicca syndrome/Sjögren's disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management.","authors":"Sandra Gofinet Pasoto, André Silva Franco, Clovis Artur Silva, Eloisa Bonfa","doi":"10.1080/1744666X.2024.2370327","DOIUrl":"10.1080/1744666X.2024.2370327","url":null,"abstract":"<p><strong>Introduction: </strong>Almost one-quarter of immune checkpoint inhibitor (ICI) recipients experience sicca syndrome, while Sjögren's disease (SjD) is estimated at 0.3-2.5%, possibly underreported.</p><p><strong>Areas covered: </strong>This narrative review (Medline/Embase until January/31/2024) addresses the pathophysiology, incidence, demographic/clinical features, biomarkers, labial salivary gland biopsy (LSGB), fulfillment of the idiopathic SjD (iSjD) classificatory criteria, differential diagnosis, and management of sicca syndrome/SjD associated with ICIs.</p><p><strong>Expert opinion: </strong>SjD associated with ICIs is underdiagnosed, since studies that performed the mandatory SjD investigation identified that 40-60% of patients with sicca syndrome associated with ICIs meet the iSjD classificatory criteria. LSGB played a fundamental role in recognizing these cases, as most of them had negative anti-Ro/SS-A antibody. Despite the finding of focal lymphocytic sialoadenitis in LSGB samples mimicking iSjD, immunohistochemical analysis provided novel evidence of a distinct pattern for sicca syndrome/SjD associated with ICIs compared to iSjD. The former has scarcity of B lymphocytes, which are a hallmark of iSjD. Additionally, patients with sicca syndrome/SjD associated with ICIs have demographical/clinical/serological and treatment response dissimilarities compared to iSjD. Dryness symptoms are more acute in the former than in iSjD, with predominance of xerostomia over xerophthalmia, and partial/complete response to glucocorticoids. Dryness symptoms in ICI-treated patients warrant prompt SjD investigation.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1149-1167"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of subcutaneous immunotherapy with polymerized allergen mixtures in polyallergic patients - ARES observational study. 多过敏原患者使用聚合过敏原混合物皮下免疫疗法的有效性和安全性。ARES 观察性研究。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-02 DOI: 10.1080/1744666X.2024.2373886
Marcela Santaolalla, José Arias-Irigoyen, Jose Miguel Soler, José María Duque, Rosario Escudero, José Luis Pérez-Formoso, Teófilo Lobera, María Rueda, César Alias, Helena Hermida, Catalina Vela, Leire Begoña, Alexander Vazquez, Begoña Madariaga

Background: Administration of allergen mixtures of many components comprises the most common approach for American allergists regarding the management of polyallergic patients. European allergists, however, are more reluctant to this type of treatment due to the potential drawbacks of mixing extracts.

Research design and methods: To assess the efficacy and safety of subcutaneous immunotherapy (SCIT) with polymerized allergen mixtures without dilutional effect in polyallergic patients.This observational, prospective, multicenter study included patients (between 5 and 60 years) with respiratory allergic diseases that had been prescribed with SCIT with mixtures of two pollen or mite extracts. Changes in Symptoms and Medication Score (SMS) and in rhinitis quality of life questionnaire (RQLQ), subjective clinical improvement, treatment satisfaction and tolerability were assessed after the 1-year treatment.

Results: A total of 115 patients were included in the assessment. Mean global SMS decreased from 3.5 (SD = 1.1) to 1.6 (SD = 1.2) points, with a mean absolute reduction of 1.6 (SD = 1.3) points in the RQLQ score (p < 0.001, Wilcoxon test). General subjective clinical improvements and a good treatment satisfaction and tolerability were observed.

Conclusion: SCIT with polymerized allergen mixtures from either pollen or mite extracts proved to be an effective and safe treatment option for polyallergic patients suffering from allergic respiratory diseases.

背景:美国过敏症医生在治疗多过敏症患者时最常用的方法是使用多种成分的过敏原混合物。然而,由于混合提取物可能存在的弊端,欧洲过敏学家更不愿意采用这种治疗方法:这项观察性、前瞻性、多中心研究纳入了呼吸道过敏性疾病患者(5-60 岁),他们都曾接受过两种花粉或螨虫提取物混合物的皮下免疫疗法(SCIT)。结果显示,115 名患者接受了为期一年的治疗,评估了症状和用药评分(SMS)、鼻炎生活质量问卷(RQLQ)、主观临床改善、治疗满意度和耐受性的变化:结果:115 名患者参与了评估。SMS平均值从3.5(SD = 1.1)分下降到1.6(SD = 1.2)分,RQLQ平均值绝对值下降了1.6(SD = 1.3)分(p 结论:SCIT与聚合过敏原治疗的疗效一致:使用花粉或螨虫提取物的聚合过敏原混合物进行 SCIT,对于患有过敏性呼吸道疾病的多过敏体质患者来说,是一种有效且安全的治疗方法。
{"title":"Efficacy and safety of subcutaneous immunotherapy with polymerized allergen mixtures in polyallergic patients - ARES observational study.","authors":"Marcela Santaolalla, José Arias-Irigoyen, Jose Miguel Soler, José María Duque, Rosario Escudero, José Luis Pérez-Formoso, Teófilo Lobera, María Rueda, César Alias, Helena Hermida, Catalina Vela, Leire Begoña, Alexander Vazquez, Begoña Madariaga","doi":"10.1080/1744666X.2024.2373886","DOIUrl":"10.1080/1744666X.2024.2373886","url":null,"abstract":"<p><strong>Background: </strong>Administration of allergen mixtures of many components comprises the most common approach for American allergists regarding the management of polyallergic patients. European allergists, however, are more reluctant to this type of treatment due to the potential drawbacks of mixing extracts.</p><p><strong>Research design and methods: </strong>To assess the efficacy and safety of subcutaneous immunotherapy (SCIT) with polymerized allergen mixtures without dilutional effect in polyallergic patients.This observational, prospective, multicenter study included patients (between 5 and 60 years) with respiratory allergic diseases that had been prescribed with SCIT with mixtures of two pollen or mite extracts. Changes in Symptoms and Medication Score (SMS) and in rhinitis quality of life questionnaire (RQLQ), subjective clinical improvement, treatment satisfaction and tolerability were assessed after the 1-year treatment.</p><p><strong>Results: </strong>A total of 115 patients were included in the assessment. Mean global SMS decreased from 3.5 (SD = 1.1) to 1.6 (SD = 1.2) points, with a mean absolute reduction of 1.6 (SD = 1.3) points in the RQLQ score (<i>p</i> < 0.001, Wilcoxon test). General subjective clinical improvements and a good treatment satisfaction and tolerability were observed.</p><p><strong>Conclusion: </strong>SCIT with polymerized allergen mixtures from either pollen or mite extracts proved to be an effective and safe treatment option for polyallergic patients suffering from allergic respiratory diseases.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1281-1292"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Connecting salivary gland inflammation to specific symptoms in Sjögren's disease. 将唾液腺炎症与 Sjögren 病的特定症状联系起来。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-21 DOI: 10.1080/1744666X.2024.2377616
Niels Roelof Franciscus Sluijpers, Sarah Pringle, Hendrika Bootsma, Frederik Karst Lucien Spijkervet, Arjan Vissink, Konstantina Delli

Introduction: The complex nature of Sjögren's Disease (SjD) necessitates a comprehensive and patient-centered approach in both diagnosis and management. This narrative review emphasizes the need for a holistic understanding of the connection between salivary gland inflammation and oral symptoms in SjD.

Areas covered: The intricate relationship between salivary gland inflammation and dry mouth is explored, highlighting the variability in associations reported in studies. The association of the severity of xerostomia and degree of inflammation is also discussed. The frequent presence of recurrent sialadenitis in SjD further accentuates the connection of compromised salivary gland function and inflammation. The review additionally discusses local inflammatory factors assessed through salivary gland biopsies, which could potentially serve as predictors for lymphoma development in SjD. Insights into compromised quality of life and hypercoagulable state and their association with salivary gland inflammations are provided. Advancements in noninvasive imaging techniques, particularly salivary gland ultrasonography and color Doppler ultrasound, offer promising avenues for noninvasive assessment of inflammation.

Expert opinion: There is a need for longitudinal studies to unravel the connections between salivary gland inflammation and oral symptoms. This will enhance management strategies and optimize treatment outcomes for SjD patients.

导言:斯约格伦病(Sjögren's Disease,SjD)性质复杂,需要在诊断和管理方面采取全面和以患者为中心的方法。这篇叙述性综述强调了全面了解唾液腺炎症与 SjD 口腔症状之间联系的必要性:本综述探讨了唾液腺炎症与口干之间错综复杂的关系,强调了研究报告中各种关联的差异性。还讨论了口腔干燥症的严重程度与炎症程度之间的关系。在 SjD 患者中经常出现的复发性唾液腺炎症进一步强调了唾液腺功能受损与炎症之间的联系。该综述还讨论了通过唾液腺活检评估的局部炎症因子,这些因子有可能成为预测 SjD 淋巴瘤发展的指标。文章还深入探讨了生活质量下降和高凝状态及其与唾液腺炎症的关系。无创成像技术的进步,尤其是唾液腺超声造影和彩色多普勒超声,为无创评估炎症提供了前景广阔的途径:专家意见:有必要进行纵向研究,以揭示唾液腺炎症与口腔症状之间的联系。专家观点:有必要开展纵向研究,以揭示唾液腺炎症与口腔症状之间的联系,从而加强管理策略,优化斯约格伦病(SjD)患者的治疗效果。
{"title":"Connecting salivary gland inflammation to specific symptoms in Sjögren's disease.","authors":"Niels Roelof Franciscus Sluijpers, Sarah Pringle, Hendrika Bootsma, Frederik Karst Lucien Spijkervet, Arjan Vissink, Konstantina Delli","doi":"10.1080/1744666X.2024.2377616","DOIUrl":"10.1080/1744666X.2024.2377616","url":null,"abstract":"<p><strong>Introduction: </strong>The complex nature of Sjögren's Disease (SjD) necessitates a comprehensive and patient-centered approach in both diagnosis and management. This narrative review emphasizes the need for a holistic understanding of the connection between salivary gland inflammation and oral symptoms in SjD.</p><p><strong>Areas covered: </strong>The intricate relationship between salivary gland inflammation and dry mouth is explored, highlighting the variability in associations reported in studies. The association of the severity of xerostomia and degree of inflammation is also discussed. The frequent presence of recurrent sialadenitis in SjD further accentuates the connection of compromised salivary gland function and inflammation. The review additionally discusses local inflammatory factors assessed through salivary gland biopsies, which could potentially serve as predictors for lymphoma development in SjD. Insights into compromised quality of life and hypercoagulable state and their association with salivary gland inflammations are provided. Advancements in noninvasive imaging techniques, particularly salivary gland ultrasonography and color Doppler ultrasound, offer promising avenues for noninvasive assessment of inflammation.</p><p><strong>Expert opinion: </strong>There is a need for longitudinal studies to unravel the connections between salivary gland inflammation and oral symptoms. This will enhance management strategies and optimize treatment outcomes for SjD patients.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1169-1178"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Review of Clinical Immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1